Estradiol-3-benzoate-17-butyrate (63042-18-2) hplc≥99% | AASraw
AASraw produces Cannabidiol(CBD) powder and Hemp Essential Oil in bulk!

Estradiol-3-benzoate-17-butyrate (63042-18-2)

Rating: SKU: 63042-18-2. Category:

AASraw is with synthesis and production ability from gram to mass order of Estradiol-3-benzoate-17-butyrate (63042-18-2), under CGMP regulation and trackable quality control system.

Product Description


Estradiol-3-benzoate-17-butyrate (63042-18-2) video




Estradiol-3-benzoate-17-butyrate (63042-18-2) Specification:

Chemical Structure: Product Name: Estradiol-3-benzoate-17-butyrate
Estradiol-3-benzoate-17-butyrate (63042-18-2) hplc≥99% | AASraw Cas No.: 63042-18-2
Molecular Formula: C29H34O4
Molecular Weight: 446.6
Synonyms: Estradiol-3-benzoate-17-butyrate


EINECS 263-807-9



Storage: Dry, dark
Documents(COA & HPLC etc.): Available


Estradiol-3-benzoate-17-butyrate (63042-18-2) Description:

Estradiol-3-benzoate-17-butyrate(Estradiol benzoate butyrate, EBB), sold under the brand names Redimen, Soluna, and Unijab and formerly known under the developmental code name Unimens, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide (DHPA; algestone acetophenide), a progestin, and is used specifically as a combined injectable contraceptive. EBB is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.

EBB is a synthetic estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen.



  • 1, Toppozada M (1977). “The clinical use of monthly injectable contraceptive preparations”. Obstet Gynecol Surv. 32 (6): 335–47. doi:10.1097/00006254-197706000-00001. PMID 865726.
  • 2, Mokhtar K. Toppozada (1983), Monthly Injectable Contraceptives
  • 4, Amit K. Ghosh (23 September 2010). Mayo Clinic Internal Medicine Board Review. OUP USA. pp. 222–. ISBN 978-0-19-975569-1.
  • 5, Kuhl H (2005). “Pharmacology of estrogens and progestogens: influence of different routes of administration” (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947